Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1.

Kilickap S., Baramidze A., Sezer A., Özgüroğlu M., Gumus M., Bondarenko I., ...Daha Fazla

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, cilt.20, ss.941-954, 2025 (SCI-Expanded, Scopus)